Compare Toro Company (The) Common Stock (TTC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toro Company (The) Common Stock vs Zoetis Inc — how do they compare? Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B), while Zoetis Inc trades at $76 (market cap $30.70B). The key difference: Zoetis Inc is far larger — about 3.3× Toro Company (The) Common Stock's market cap, and Zoetis Inc pays the higher dividend (2.85%). Which is the better fit depends on your goals — on Pluang, investors hold Toro Company (The) Common Stock for 0 Days and Zoetis Inc for 71 Days on average.
| TTC | ZTS | |
|---|---|---|
Market Cap | $9.27B | $30.70B |
Volume | 688,325 | 3,299,421 |
Sector | Industrials | Health |
52-Week High | $101.76 | $147.53 |
52-Week Low | $67.99 | $69.09 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $10.17B | $38.27B |
Dividend Yield | 1.59% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Zoetis (ZTS) trades at $75.335, down 0.42% on the day, with a bullish technical signal from moving averages and ADX indicators. The company reported strong profitability with a 27.69% net income margin and 64.91% ROE for 2025, though Q1 2026 EPS missed expectations. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and industry-leading margins.
The outlook is cautiously optimistic, with a consensus price target of $87.33 implying 16% upside. Investment opportunities lie in Zoetis's robust fundamentals and market dominance, while risks include competitive pressures, weaker U.S. demand, and margin compression from promotions. The stock offers value at a P/E of 12.12, but investors should monitor Q3 2026 results for growth confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
